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ABSTRACT
Purpose
The purpose of this study was to determine whether the adjunctive use of plasma
rich in growth factors in postextraction sites could be beneficial in terms of hard-/
Q2 soft-tissue healing and patients’ comfort.
Materials and Methods
An electronic search was performed on MEDLINE, EMBASE, Scopus, and CEN-
TRAL. Only controlled clinical trials or randomized clinical trials that used plasma
rich in growth factors in the test group were included. The primary outcomes
were pain assessment, complications, and adverse events. Secondary outcomes
were hard-tissue healing, bone remodeling, and soft-tissue healing.
Results
Eight comparative studies (5 randomized clinical trials) were included. Four
studies had a split-mouth design. Six hundred fourteen teeth were extracted in
338 patients. Only qualitative analysis could be performed. Postoperative pain
and the incidence of complications such as alveolar osteitis were consistently
lower in the test group. Hard-tissue healing, evaluated by clinical, radiographic,
histologic, and histomorphometric techniques, showed significantly better results
for the test group in almost all studies. Better epithelialization, keratinized tissue
thickness, and healing score were also reported.
Conclusion
Plasma rich in growth factors may bring advantages in some relevant clinical and
radiographic outcomes, such as bone density and soft-tissue healing, after tooth
extraction. It could also represent a useful tool for reducing adverse events,
complications, and patients’ discomfort, although it is still not quantifiable.
INTRODUCTION
Tooth extraction, in routine dental practice, is carried out for the tooth withhopeless prognosis affected by deep dental caries, periodontitis, or
trauma or sometimes as a treatment protocol for orthodontic space creation.1
The physiological process of postextraction alveolar socket healing involves
a complex and intricate play of bone cell migration and maturation along
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with selective bone resorption and apposition.2 These
healing events are rather complicated and delayed, in
various situations, leading to vertical and/or horizontal
decrease of alveolar process dimension. During the
healing period, some complications, such as alveolar
osteitis (AO), bleeding, intense pain, infection, and trismus
or swelling, associated with postextraction sites may
arise.3 Nonetheless, inadequate bone apposition or
progressive bone resorption may occur, compromising the
placement of implant-supported prosthetic rehabilitation.
Bone loss and changes in the soft-tissue profile resulting
from tooth loss and an unpleasant esthetic aspect can also
hinder rehabilitation of the edentulous ridge using remov-
able or fixed prostheses.4
The concept of “socket preservation” with various bio-
materials is used in postextraction sites to hinder the alve-
olar process dimensional reduction and lessen the healing
complications. Various systematic reviews indicate the use
of biomaterials, such as bone substitutes, collagen sponges,
barrier membranes, and growth factors, in the post-
extraction sites and have proven their efficacy on the basis
of some clinical evidence.5-9 Moreover, these preservation
techniques may avoid additional bone augmentation at the
time of implant rehabilitation. However, the efficacy of these
alveolar socket-preservation treatments is still unclear. In a
recent systematic review, it was concluded that the alveolar
ridge resorption cannot be totally avoided; rather, it can be
prevented with the use of such preservation techniques,
although no specific technique is proved to be superior than
the others.10
Previous clinical research on the use of different biomaterials,
such as particulate hydroxyl-apatite,11 bio-active glass,12
polylactide/polyglycolic sponges,13 barrier membranes,14 and
others, for socket preservation has been documented.15 The
origin of these biological materials is rather heterogeneous,
and the cost of manufacturing processes to make them
compatible for use in human applications often translates into
an economic burden for patients. In addition, some patients
reject the use of xenografts or allografts, arguing that they are
afraid of the possibility of disease transmission from the
donor, while others refuse autologous bone grafts because of
the fear of pain and discomfort due to the harvesting
procedure.16 It has also been demonstrated that some graft
materials are not completely degraded many years after
implantation and only slightly promote osteogenic
induction,17 which also directly affects the formation of new
bone and soft-tissue healing in the tooth-extraction sockets.
The use of biologic agents such as recombinant human
bone morphogenetic protein-2, basic fibroblast growth
factors, recombinant human platelet–derived growth factor,
and transforming growth factor beta had proven to
promote osteogenic induction in cases of alveolar socket
preservation in recent studies.18,19 In addition, the use of
autologous platelet concentrates (APCs) is gaining popu-
larity as a source of a number of growth factors in high
concentrations, for regenerative treatments in many clinical
applications. The contribution of blood-derived platelets to
the bone-healing process is thought to be based on the
growth factors stored in their granules and released on
activation. APCs are advantageously used as a cost-effective
adjunct to surgical regenerative therapy, even in combina-
tion with bone grafts.20 Several systematic reviews have
reported on the efficacy of the use of these APCs in
postextraction sites, suggesting improvement of
postoperative soft-tissue healing, control of postoperative
symptoms, and adequate socket preservation.21-24
Plasma rich in growth factors (PRGF) is a biological concept
developed and introduced at the end of the 1990s.25
Among the various types of APCs, PRGF is characterized
by a relatively modest increase of the concentration of
platelets (2-3 times the serum platelet concentration), with
respect to platelet-rich plasma (5-8 times), and by the
absence of leukocytes.26 The increased concentration of
platelets delivers a wide array of platelet growth factors,
which may promote osteogenic induction and may
simultaneously facilitate soft-tissue healing in the post-
extraction sites. Various clinical trials have reported the use
of PRGF in wound healing and preservation of post-
extraction sites.25,27-30 However, no systematic review has
been published to date that evaluates the scientific quality
of these trials and the consistency among studies regarding
the effect of using PRGF in postextraction sites. The aim of
this systematic review is to investigate whether PRGF is
effective in the preservation of the postextraction alveolus.
MATERIALS AND METHODS
This systematic review was conducted based on Preferred
Reporting Items for Systematic Reviews and Meta-analysis
guidelines.31 The review protocol was registered on the
International Prospective Register of Systematic Reviews
(PROSPERO, no.: CRD42018091547).
Research Question
The research question was “Is the adjunctive use of PRGF in
postextraction sites beneficial in terms of hard-/soft-tissue
healing and patients’ comfort?”
Search Strategy
An electronic search was carried out in the following data-
bases: MEDLINE, Cochrane Central Register of Controlled
Trials (CENTRAL), SCOPUS, and EMBASE, using a series of
search terms combined with the Boolean operators “AND,”
“OR,” and “NOT.” The search string was designed using
the following keywords: (plasma OR plasma rich in growth
factors OR PRGF OR pure platelet rich plasma OR P-PRP OR
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endoret) AND (post extraction sites OR extraction socket
healing OR socket preservation OR tooth extraction OR
third molar extraction OR third molar surgery). The last
electronic search was carried out on March 2018. In addi-
tion, a hand search was performed in the following dental
journals: British Dental Journal, British Journal of Oral and
Maxillofacial Surgery, Clinical Implant Dentistry and Related
Research, Clinical Oral Implants Research, Clinical Oral In-
vestigations, European Journal of Oral Implantology, Euro-
pean Journal of Oral Sciences, Implant Dentistry,
International Journal of Oral and Maxillofacial Implants, In-
ternational Journal of Oral and Maxillofacial Surgery, Inter-
national Journal of Periodontics and Restorative Dentistry,
Journal of Clinical Periodontology, Journal of Dental
Research, Journal of Dentistry, Journal of Implantology,
Journal of Maxillofacial and Oral Surgery, Journal of Oral
and Maxillofacial Surgery, Journal of Periodontal Research,
Journal of Periodontology, andOral Surgery, Oral Medicine,
Oral Pathology, Oral Radiology. The bibliographies of the
included studies and of the reviews were also searched for
possible additional eligible studies. FinallyQ3 , we searched the
following trial registries for ongoing studies: US National
Institutes of Health Ongoing Trials Register ClinicalTrials.gov
(clinicaltrials.gov; searched on February 20, 2017) and
World Health Organization International Clinical Trials Reg-
istry Platform (apps.who.int/trialsearch; searched on
February 20, 2018).
Inclusion Criteria
The inclusion criteria for the eligible studies were as follows:
 The study had to be a comparative prospective clinical
trial (randomized or controlled) with parallel or split-
mouth design involving postextraction sites in human
subjects. Both single and multiple extraction sites were
considered.
 The study had to use PRGF alone or in adjunct to any
grafting material (eg, bone substitutes) in the experi-
mental group, and the only difference to the control
group had to be the use of PRGF.
 Studies with patients with systemic illness, with smoking
habits, or who underwent radiotherapy were included
in this review.
 No restriction on the language, sample size, follow-up
duration, or year of publication was applied.
Study Selection and Data Collection
Two independent reviewers (S.P. and M.D.F.) screened the
title and abstract of the articles retrieved from the electronic
search, based on the set of inclusion criteria. The full text of
the relevant eligible studies was further assessed indepen-
dently by the same 2 reviewers to ensure that the studies
met the inclusion criteria. The disagreements between the
reviewers were resolved by discussion, and the reasons for
exclusion were recorded for each excluded study.
Relevant data of the included studies were extracted using
an Excel spreadsheet (Microsoft, Redmond, WA).
The primary outcomes evaluated were
 Postoperative pain (measured with a visual analog
scale)
 Any adverse effects/complications such as infection,
swelling, alveolitis, AO, or any type of symptoms in the
postoperative period.
The secondary outcomes evaluated were
 Assessment of hard-tissue healing (by radiographic or
histomorphometric analysis)
 Clinical or radiographic evaluation of marginal bone
remodeling (eg, bone height at the vestibular and
lingual or palatal aspect and bone width at the extrac-
tion region)
 Assessment of soft-tissue healing (using the healing
index proposed by Landry or other standard indexes)
Risk of Bias Assessment
Risk of bias (RoB) was assessed by two independent re-
viewers (S.P. and M.D.F.) for all the included clinical trials,
and the discrepancies were resolved by discussion and in
consent with a third reviewer (S.T.). The assessment was
carried out using parameters such as random sequence
generation, allocation concealment, blinding of outcome
assessment, comparability of control and treatment groups
at entry, clear definition of inclusion and exclusion criteria,
clear definition of outcome assessment, completeness of
outcome data reporting, recall rate, sample size calculation,
and the number of surgeons involved. The criteria of RoB
assessment were modified from the guidelines reported in
the Cochrane Handbook for Systematic Reviews of In-
terventions, version 5.1.0.
The summary of the RoB assessment of the studies was
validated by grading them into high, medium, or low risk. A
study was considered to be at high risk if it was found to
have two or more of the assessed parameters classified at
high risk or one parameter at high risk and three or more at
uncertain risk; it was considered to be at medium risk if one
of the parameters was classified at high risk and no more
than two at uncertain risk; and it was considered to be at low
risk if none of the parameters was classified at high risk and
no more than three at uncertain risk.
Data Analysis
The data from different studies were combined by meta-
analysis only when at least two studies with similar
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comparisons were found, reporting the same outcome
measurements at comparable observation times after tooth
extraction. For each trial, for dichotomous outcomes (such as
postoperative AO recorded as yes or no), the estimation of
the effect of an intervention is expressed as risk ratios with
95% confidence intervals (CIs). For continuous outcomes
(such as percentage of newly formed bone and alveolar
bone height and width changes), mean differences with 95%
CIs were used to synthesize data for each treatment group.
The statistical analysis unit was, if possible, the patient, un-
less all compared studies expressed the results using the
tooth as the unit of analysis. If a meta-analysis could not be
performed for a given outcome, then a qualitative report of
the results is provided. Risk ratios for dichotomous data and
mean differences for continuous data were combined using
random-effects models if at least 4 studies could be included
in the meta-analysis; otherwise, a fixed-effects model was
adopted. Review Manager 5.3 (The Nordic Cochrane Center,
The Cochrane Collaboration, Copenhagen, Denmark) was
used for meta-analysis calculations and graphs.
RESULTS
The electronic search retrieved a total of 694 articles. After
discarding the duplicates, unrelated records, and articles
excluded for specific reasons, 8 studies were included for
qualitative analysis in this review (Figure 1).25,27-30,32-34
The main features of the included studies are summarized in
Tables 1 and 2. The excluded studies are listed in Table 3,
with reasons for their exclusion.35-41
Primary Outcomes
Postoperative Pain
Five out of 8 studies evaluated postoperative pain for a
follow-up duration of 7 days.27-29,33,34 The studies reveal
that postoperative pain was comparatively lesser in the
postextraction sites treated with PRGF than the control sites.
Postoperative pain was almost absent in the PRGF-treated
sites in one of the studies,27 having the scores of 0.17 and
0.00 at day 3 (P , .001) and day 7 (P , .03), respectively
(Table 4).
Adverse Events/Complications
In one of the included trials that had the occurrence of AO
as the primary outcome, lower incidence of AO and acute
inflammation was documented in the PRGF-treated sites
than in control sites.29 In the split-mouth study, 18 of 40
patients presented with AO in the control sites, whereas
only 4 cases of AO occurred in the sites treated with PRGF in
patients who also developed AO on the control site.29
In another study, PRGF was as effective as fibrin glue for
prevention of severe bleeding in patients with blood coa-
gulopathies and thrombocytopenia.32
Secondary Outcomes
Hard-tissue Healing
The included trials have evaluated hard-tissue healing under
a variety of assessments such as clinical, radiological, his-
tologic, and histomorphometric analyses.
Residual socket volume (RSV) was the parameter used to
clinically assess hard-tissue healing in two studies28,33 and
was found to be better in the sites treated with PRGF. RSV
was calculated as the ratio of the socket dimensions at each
follow-up to the socket dimensions at baseline. Both the
studies28,33 used RSV evaluation at 7th, 14th, and 21st day
of postextraction follow-up. Comparisons between values
relative to the experimental and control sides showed better
healing and faster socket closure for the side treated with
PRGF, with differences statistically significant at day 7 and
borderline at day 14. Because no other included study used
this parameter, its relevance is limited.
One study carried out radiological assessment using
cone-beam computerized tomographical analysis.27 The
study claimed to have higher (P , .001) percentage of
regenerated sockets (96.7%), higher (P , .001)
regenerated socket volume (96.5 6 8.0%), higher (P ,
.001) radiodensity (Hounsfield unit) of bone formed
(450.0 6 106.7), and faster bone formation at the
postextraction sites treated with PRGF than at the control
sites. The study also reported higher new bone formation
(P , .049) under histomorphometric analysis in the sites
Figure 1. Flow diagram of the study selection process.
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with PRGF (63.1 6 13.8%) than that in control sites
(35.6 6 35.3%).27 Histologic analysis showed better bone
quality in biopsies from sites treated with PRGF than in
those from control sites.25
On the contrary, one study reported that the PRGF-treated
group did not show any enhancement in early (4 and
8 weeks) bone deposition in comparison with the control
group.30
Soft-tissue Healing
Better epithelialization was seen in the sites treated with
PRGF. Epithelialization was rather rapid and excellent
compared with that in control sites.25 The measurement of
the thickness of the epithelial layer indicated a thicker
layer in the sockets treated with PRGF. The thickness of
keratinized gingiva (140.6 mm; 95% CI: 70.41–210.81; P ,
.038) was higher in the PRGF group than that in the
control group.27
In diabetic subjects, soft-tissue healing was significantly
faster and better with the use of PRGF at test sites.28 The
difference between the healing index scores was found to
be highly significant at 3, 7, and 14 days (P , .05).
However, at the end of 21 days, the healing index scores
were pretty similar and not significant (P 5 .33) in both
PRGF (4.0 6 0.2) and control groups (4.1 6 0.4).28
Risk of Bias
The RoB summary is presented in Figure 2. Four studies
were classified as having a low RoB,25,27,29,32 two as
having a medium risk,28,33 and two as having a high
RoB.30,34
DISCUSSION
The aim of this systematic review was to assess the clinical
studies that evaluated the effect of adjunctive use of PRGF
in postextraction sites and critically appraise the same in
terms of the listed primary and secondary outcomes. A total
Table 1. Main characteristics of the included studies.
Study
Study
design
Patients
(N)
Age, mean
(range)
Teeth (n) Intervention
Follow-upTest Control Test Control
Anitua et al.,
201527
RCT 60 T: NR (29 – 74);
C: NR (18 – 67)
36 24 PRGF None 10-12 wks
Cocero et al.,
201532
RCT 120 NR (6 - 78) 98 106 PRGF Fibrin glue 1 wk
Mozzati et al.,
201428
RCT
(sm)
34 62.7 6 12.2 (NR) 34 34 PRGF None 3 wks
Mozzati et al.,
201433
CCT
(sm)
20 63 6 8 (NR) 57 57 PRGF in
irradiated
area
None in
nonirradiated
area
3 wks
Farina et al.,
201330
CCT 28 55.2 (34 – 74) 18 18 PRGF None 4-6 wks
(T1 5 1 m),
7-10 wk
(T2 5 2 m)
Haraji et al.,
201229
CCT
(sm)
40 22.1 6 1.7 (18 - 45) 40 40 PRGF None Up to 7 d
Mozzati et al.,
201034
RCT
(sm)
16 22.5 (18 - 35) 16 16 PRGF No PRGF Up to 1 wk
Anitua,
199925
RCT 20 T- 41 (35 - 55)
C- 42 (38 - 54)
10 10 PRGF 6 ABG ABG 10 to 16 wks
ABG, autogenous bone graft; C, control group; CCT, controlled clinical trial; NR, not reported; PRGF, plasma rich in growth factors; RCT, randomized
clinical trial; sm, split-mouth; T, test group.
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Table 2. Methods and results of the included studies.Q6
Study Teeth treated
Postsurgical
complications Study outcomes Effect of PRGF
Anitua et al.,
201527
Mandibular molar
(1st, 2nd, and 3rd)
1 PRGF/1 CTRL
(tumefaction); 0
PRGF/0 CTRL
(infection)
1. Percentage of
regenerated sockets.
2. Percentage regenerated
volume, bone density;
pain; soft-tissue healing
score; inflammation score;
histomorphometric
analysis—percentage of
new bone formation;
keratinized gingival
thickness
PRGF-treated sites
enhanced hard- and soft-
tissue healing of sockets
with better epithelialization
and increased thickness of
keratinized epithelium with
the absence of
inflammation. The sites
also presented with almost
negligible postoperative
pain.
Cocero et al.,
201532
Molar, premolar,
canine, incisor
2 PRFG/3
CTRL (severe
secondary
bleeding)
Number of complications;
bleeding rate after 7-day
follow-up period
PRGF works as well as fibrin
glue as a local hemostatic
agent to control for
bleeding after extraction.
Mozzati et al.,
201428
NR NR 1. Residual socket volume;
pain; healing index, and
postsurgical complications.
2. Patient satisfaction;
effects of smoking habits,
HA1C, EODS, and
glycemia on socket
reduction.
PRGF application after
extraction improved the
healing process in diabetic
patients by accelerating
socket closure
(epithelialization) and
tissue maturation, proving
the association between
PRGF use and improved
wound healing in diabetic
patients.
Mozzati et al.,
201433
Bilateral similar
teeth (all types)
0 PRGF/2 CTRL
(bone exposure
with soft-tissue
necrosis)
Residual socket volume;
pain; healing index, and
postsurgical complications
PRGF proved to be
effective in the
management of patients
with a history of head and
neck radiotherapy,
accelerating and fostering
mucosal healing and
avoiding postextraction
bone exposures.
Farina et al.,
201330
Single-rooted tooth
or single roots
of hemisected
mandibular
molars.
NR Micro-CT analysis,
histologic and
histomorphometric
evaluation for bone
deposition.
PRGF-treated group did
not show any enhancement
in early (4 and 8 weeks)
bone deposition compared
with the control group.
Haraji et al.,
201229
Maxillary and
mandibular
third molars
AO (outcome);
4 PRGF/18 CTRL
Alveolar osteitis, pain,
healing score
The application of PRGF
may significantly reduce
the incidence of AO or its
associated pain and may
accelerate healing. The
prophylactic use of PRGF
after third-molar extraction
may be suggested
especially in the patients at
risk of AO.
(continued )
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of 8 clinical trials were included and analyzed in this review.
Most of the studies were judged as having a medium to
high quality based on the criteria set for the RoB assess-
ment. The lack of at least 2 studies with similar data set for
any outcome variables prevented us from carrying out a
standard meta-analysis and presenting the results through a
forest plot. However, the qualitative analysis was rigorously
performed to get the best conclusion about the efficacy of
the adjunctive use of PRGF in postextraction sites.
One study29 used AO as the primary outcome and reported
that there was significantly lower incidence of AO in the
sites treated with PRGF than in control sites. Indeed, very
few studies reported adverse events or postsurgical
complications, such as tumefaction, infection, and
bleeding, in the postextraction sites treated with PRGF at
the end of follow-up (Table 2). Although it was not
possible to perform a quantitative evaluation regarding
the various complications, the qualitative synthesis proved
to be in favor of using PRGF in postextraction sites to
lower the incidence of postsurgical complications. One
controversial question is regarding the feasibility of using
autologous hemocomponents when the subjects are
affected by hematological diseases. The study that
recruited the subjects with blood disorders, for example,
coagulopathies and thrombocytopenia, in need of
extraction suggested that PRGF can represent an effective
Table 2. Continued
Study Teeth treated
Postsurgical
complications Study outcomes Effect of PRGF
Mozzati et al.,
201034
Impacted
mandibular
third molars
NR Inflammatory cytokines
(real-time PCR): IL-1b, IL-6,
IL-10, TGF-b2, BMP-2,
BMP-4; clinical parameters
and pain; facial swelling
Postoperative pain and the
swelling, measured at all
experimental times, were
reduced in the presence of
PRGF. The cytokine profile
in the PRGF was favorable
for enhanced and
unprecedented healing
Anitua, 199925 All types 1 PRGF/1 CTRL Biopsy and histological
analysis
No negative effect has
been found in the use of
PRGF. Better
epithelialization and
osseous regeneration of
mature bone has been
found in a larger quantity
and quality than in control
areas.
AO, alveolar osteitis; CTRL, control; NR, not reported; PRGF, plasma rich in growth factors; TGF-b, transforming growth factor beta.
Table 3. List of excluded studies with reasons for exclusion.
Excluded study Reason for exclusion
King et al.,
201835
PRGF used in postextraction sites with
alveolar osteitis
Ntounis et al.,
201536
Use of PRP as the experimental group
Geurs et al.,
201437
Use of PRP as the experimental group
Mozzati et al.,
201138
Case-control study in patients on
intravenous bisphosphonate therapy;
the occurrence of bisphosphonate-
related osteonecrosis of the jaw was
the only outcome reported.
Anitua et al.,
201539
Case series
Nazaroglou et al.,
200940
Case report
Anitua, 200141 Report of two cases
PRGF, plasma rich in growth factors.
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local hemostatic agent similar to fibrin glue, controlling the
incidence of severe secondary bleeding.32
Proper hard- and soft-tissue healing are the predictable
outcomes to evaluate the success of alveolar socket pres-
ervation. In this review, six studies assessed the pattern of
hard-tissue healing at different time points and with
different outcomes: socket depth/dimension reduction,
percentage of sockets with regenerated bone, bone density,
and histologic and histomorphometric parameters.25,27-30,33
The variability of assessment methods for evaluating hard-
tissue healing in the different studies did not allow for
quantitative evaluation of the effect of PRGF on such
outcomes. Nevertheless, the trend of the studies suggested
a positive effect of PRGF because most of them concluded
that there is evidence of potential of PRGF in effective hard-
tissue regeneration, in terms of newly formed bone quality
and quantity.
On the other hand, one of the included studies30 reported
that the effect of PRGF on new bone formation/deposition
was rather nonbeneficial. That study concluded that the
PRGF-treated group did not show any enhancement in early
(4 and 8 weeks) bone deposition in comparison with the
control group. However, the study was found to have strong
biases and was critically questioned on its experimental
design.42 In fact, in that study, all the subjects who had
smoking habits and all those with teeth extracted due to
periodontal disease were included in the PRGF group
(representing more than 50% of cases: 6 out of 11), whereas
no patient with a history of periodontitis or smoking habits
was allocated to the control group.30 A question was also
raised regarding the protocol of allowing the sites with
PRGF to heal by secondary intention as in this article; it was
unclear if sutures were systematically applied or not.30 In
fact, even though adhesive properties of PRGF should
keep it in place, there exists a chance of dislodgement or
Figure 2. Risk of bias summary.Table 4. Postoperative pain outcomes.Q7
Study
Study
design Postoperative pain outcomes
Anitua
et al.,
201527
RCT (P) The postoperative pain was
almost absent in the PRGF-
treated sites, having the
scores of 0.17 and 0.00 at day
3 (P , .001) and day 7
(P , .03), respectively,
compared with that in control
sites. There was a highly
statistical difference between
the two.
Mozzati
et al.,
201428
RCT
(SM)
VAS score for postoperative
pain was similar in both sides,
dropping to zero after 4 days.
Mozzati
et al.,
201433
CCT
(SM)
VAS score for postoperative
pain dropped to zero at day 4
in PRGF-treated sites
compared with control sites
(at day 6).
Haraji
et al.,
201229
CCT
(SM)
The VAS score for
postoperative pain intensity
was constantly lower in the
PRGF group than that in
control sites at all observation
times but achieved
significance at the end of the
4th day (1.69 vs 2.19).
Mozzati
et al.,
201034
RCT
(SM)
VAS score for postoperative
pain for PRGF-treated sites
(0.19 cm) was significantly
lower than that for control
sites (0.49 cm), suggesting
61.22% reduction at the end
of 7 days.
CCT, controlled clinical trial; PRGF, plasma rich in growth factors; RCT,
randomized clinical trial; VAS, visual analog scale.
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escaping of the PRGF gel into the oral cavity if not secured by
sutures, leading tononeffectiveness of PRGF.42MoreoverQ4 , the
study did notmention the sites of extraction, if not bilateral or
one tooth/arch that could result in crossover effect. The high
number of biasesmade the results of this study unreliable and
might be a reason for its findings being not in line with the
other studies.
Indeed, also in other included studies, there was no explicit
mention of the application of sutures to secure PRGF in situ
at the end of the surgical procedure, which may be
considered a sort of bias for these studies.25,28,29,33
Better epithelialization and enhanced socket healing were
reported in 4 studies.25,27,28,33 Keratinized gingiva formed on
the sites of healing sockets was significantly thicker in the
PRGFgroup. The inflammationwas found to lesser in the sites
treated with PRGF and resolved faster. ThisQ5 finding is in
concordance with findings of other studies using different
platelet concentrates such as PRP, which may limit inflam-
mation, interacting with macrophages to improve tissue
healing and regeneration,43 promote new capillary growth,44
and accelerate epithelialization45 in chronic wounds. It was
also found that the PRGF had an advantage in enhancing
soft-tissue healing and reducing the extent of inflammation
in subjects with delayed healing in case of diabetes melli-
tus.28 The dissolution time of PRGF in vivo has never been
evaluated, but the kinetics of growth factor delivery by
PRGF has been studied in vitro.46 After a rapid initial release
of platelet granules’ content in the first hour, the gel-like
PRGF kept on releasing growth factors up to 8 days of incu-
bation.46 After that time, almost 30% of the growth factor
amount was retained in the fibrin matrix. Another in vitro
study, performed under different experimental conditions,
reported that the PRGF membrane, after a slow but
continuous release of growth factors, dissolves within 5 days
of incubation.47 Of course, the in vivo kinetics release and
matrix dissolution might be different. Nevertheless, the
sustained release of growth factors could explain the
reported beneficial effects of PRGF on soft tissues in the
first week after extraction. On the other hand, it is still
controversial if PRGF may have a stimulating effect on bone
tissue because of the slow healing of the latter. However, it
may be hypothesized that the fast and predictable soft-
tissue closure at postextraction sites observed with PRGF
may also have a positive protective effect for the healing of
underlying hard tissues, triggering the bone-healing process
and controlling the incidenceof postoperative contamination
of the site and of postoperative discomfort.
Regarding the effect of the adjunct of PRGF on postoperative
quality of life, no quantitative evaluation through meta-
analysis could be performed because of differences in
methods of assessing the outcome and in reporting the re-
sults. In fact, regarding pain evaluation using a visual analog
scale, a few studies27,29,34 assessed the mean of scores ach-
ieved on a 10-point scale and others28,33 assessed the follow-
up day at which the score drops to zero. One study reported
mean values and standard deviations,27 another study only
reported the values on a graph,34 and another one did not
report the standard deviation.29 Two studies reported pain
daily,27,34 and others reported the mean values only on
selected days.29 Nevertheless, the trend of the studies
evaluating quality of life was in favor of a reduction of the
intensity of postoperative pain and symptoms in patients
treated with the adjunct of PRGF, suggesting that the use of
PRGF may be beneficial for postoperative pain control. This
is in agreement with what was reported for other clinical
applications such as maxillary sinus floor elevation48 and
endodontic surgery.49
Finally, some limitations of this review should be acknowl-
edged. For example, no distinction was made between
studies dealing with single extraction sites and studies in
which multiple extraction sites were treated, and no corre-
lation was attempted between the effect of the treatment
and other potential confounding factors, such as the socket
location, the reason for extraction, and the presence and
condition of the adjacent teeth and alveolar bone. Indeed,
because almost no study provided individual patients’ data,
such correlations were unfeasible in this systematic review. It
is recommended that in future studies, the individual pa-
tients’ data are reported in detail to determine the weight of
the aforementioned factors on the treatment outcomes.
CONCLUSION
Qualitative analysis of the studies suggested that PRGFs
could represent a useful tool for improving postextraction
hard- and soft-tissue healing and reducing adverse events,
complications, and patients’ discomfort. However, because
a quantitative analysis could not be performed, the actual
benefits of PRGF on healing and pain control in extraction
sockets are still not quantifiable. More studies, with stan-
dardized protocols, are needed to confirm and strengthen
the results of this review.
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